Annovis Bio (ANVS) Regains NYSE American Compliance Before Cure Period Expiration

Annovis Bio Inc. (NYSE American: ANVS) has regained compliance with the exchange’s continued listing standards, the company said on May 27, 2026, ending a deficiency that had triggered an 18-month cure period. The biopharmaceutical company had been notified by NYSE American that it failed to meet the minimum bid price rule, which requires a closing price of at least $0.20 per share. To cure the deficiency, Annovis completed a 1-for-10 reverse stock split in early 2026, pushing the stock above the threshold. The price has remained compliant since. With the notice rescinded, the stock continues trading on NYSE American under the symbol ANVS. The company had faced a deadline later this year to regain compliance or face delisting. The early remediation removes that risk.